Injectable PrEP study for Latine transgender women and gay men
Part of Infections clinical trials.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned male at birth.
- You are HIV-negative and have had sex with someone assigned male at birth, or you identify as a gay, bisexual man or transgender woman.
- You identify as Hispanic and/or Latine.
- You are 18 years old or older.
- You weigh at least 77 pounds (35 kilograms).
- You are interested in trying a long-acting injectable PrEP (lenacapavir) and willing to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
This study is for people who are already taking or about to start long-acting injectable HIV PrEP (shots instead of daily pills). The goal is to learn about your experiences and preferences with this type of PrEP. It takes place in Louisville, Kentucky.
This study tests ways to help Latino men who have sex with men use PrEP, a medicine that helps prevent HIV. You may be invited if you are HIV-negative (or your status is unknown), are not currently on PrEP, and can read and write Spanish.
This study tests if starting a new HIV prevention shot (lenacapavir) on the same day you see a doctor and having a say in your follow-up care can help people stick with their prevention routine. It may be an option for you if you are looking for a long-acting HIV prevention method.
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.